=Paper=
{{Paper
|id=None
|storemode=property
|title=None
|pdfUrl=https://ceur-ws.org/Vol-952/keynotemartin.pdf
|volume=Vol-952
}}
==None==
<pdf width="1500px">https://ceur-ws.org/Vol-952/keynotemartin.pdf</pdf>
<pre>
                                                                                               	
  
Keynote	
  
	
  
Ann Marie Martin, Principal Scientific Manager, Knowledge
Management, European Innovative Medicine Initiative : Joining
private and public forces to boost innovation in healthcare: the
innovative medicines initiative and knowledge management
	
  
IMI is a public-private partnership between the European Union, represented by the European
Commission, and the pharmaceutical industry, represented by the European Federation of
Pharmaceutical Industries and Associations (EFPIA). IMI’s total budget amounts to €2
billion. €1 billion is invested from the European Commission’s Seventh Framework
Programme (FP7), which is matched by contributions from EFPIA and its member
companies. As output, IMI is currently funding 42 projects representing an investment of €
1.200 million (for a description http://www.imi.europa.eu/content/ongoing-projects). All
projects have a knowledge management component and IMI has concluded a memorandum of
understanding with CDISC (Clinical Data Interchange Standards Consortium) a standards
development organization well known within the Pharmaceutical industry to address the need
to use both format and content standards in the projects. Furthermore some projects have
specific knowledge management objectives including one project adopting specifically
semantic web technologies: Open PHACTS.

Ann is responsible for the Knowledge Management projects at the Innovative Medicines
Initiative (IMI) and Knowledge management aspects of the IMI collaborations. IMI is
Europe’s largest public-private initiative aiming to speed up the development of better and
safer medicines for patients. IMI supports collaborative research projects and builds
networks of industrial and academic experts in order to boost pharmaceutical innovation in
Europe and operates as joint undertaking between the European Union and the
pharmaceutical industry association EFPIA. Between 1997 and 2009, Ann Martin held
various management positions in the pharmaceutical industry as Global Head of Biostatistics
for UCB Pharma (1997-2001), Global Section Head of Statistical Programming for Novartis
(2001-2005) and Global Head Statistical Programming Operations, Standards and CDISC
Implementation at UCB Pharma (2005-2009), giving her a broad knowledge on drug
development and extensive international experience with Europe, the US and India. Between
1987 and 1997, Ann worked for Bristol-Myers-Squibb both as a Junior and Project
Biostatistician in multiple therapeutic areas, following a short period as research assistant at
the University of Lancaster (1985-1987). Ann Martin is a Chartered Statistician and holds a
Masters degree in Sociology and Statistics from the London School of Economics and
Political Science, UK.	
  

</pre>